Tag Archives: laboratory

#437583 Video Friday: Attack of the Hexapod ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here’s what we have so far (send us your events!):

IROS 2020 – October 25-25, 2020 – [Online]
ROS World 2020 – November 12, 2020 – [Online]
CYBATHLON 2020 – November 13-14, 2020 – [Online]
ICSR 2020 – November 14-16, 2020 – Golden, Colo., USA
Let us know if you have suggestions for next week, and enjoy today’s videos.

Happy Halloween from HEBI Robotics!

Thanks Hardik!

[ HEBI Robotics ]

Happy Halloween from Berkshire Grey!

[ Berkshire Grey ]

These are some preliminary results of our lab’s new work on using reinforcement learning to train neural networks to imitate common bipedal gait behaviors, without using any motion capture data or reference trajectories. Our method is described in an upcoming submission to ICRA 2021. Work by Jonah Siekmann and Yesh Godse.

[ OSU DRL ]

The northern goshawk is a fast, powerful raptor that flies effortlessly through forests. This bird was the design inspiration for the next-generation drone developed by scientifics of the Laboratory of Intelligent Systems of EPFL led by Dario Floreano. They carefully studied the shape of the bird’s wings and tail and its flight behavior, and used that information to develop a drone with similar characteristics.

The engineers already designed a bird-inspired drone with morphing wing back in 2016. In a step forward, their new model can adjust the shape of its wing and tail thanks to its artificial feathers. Flying this new type of drone isn’t easy, due to the large number of wing and tail configurations possible. To take full advantage of the drone’s flight capabilities, Floreano’s team plans to incorporate artificial intelligence into the drone’s flight system so that it can fly semi-automatically. The team’s research has been published in Science Robotics.

[ EPFL ]

Oopsie.

[ Roborace ]

We’ve covered MIT’s Roboats in the past, but now they’re big enough to keep a couple of people afloat.

Self-driving boats have been able to transport small items for years, but adding human passengers has felt somewhat intangible due to the current size of the vessels. Roboat II is the “half-scale” boat in the growing body of work, and joins the previously developed quarter-scale Roboat, which is 1 meter long. The third installment, which is under construction in Amsterdam and is considered to be “full scale,” is 4 meters long and aims to carry anywhere from four to six passengers.

[ MIT ]

With a training technique commonly used to teach dogs to sit and stay, Johns Hopkins University computer scientists showed a robot how to teach itself several new tricks, including stacking blocks. With the method, the robot, named Spot, was able to learn in days what typically takes a month.

[ JHU ]

Exyn, a pioneer in autonomous aerial robot systems for complex, GPS-denied industrial environments, today announced the first dog, Kody, to successfully fly a drone at Number 9 Coal Mine, in Lansford, PA. Selected to carry out this mission was the new autonomous aerial robot, the ExynAero.

Yes, this is obviously a publicity stunt, and Kody is only flying the drone in the sense that he’s pushing the launch button and then taking a nap. But that’s also the point— drone autonomy doesn’t get much fuller than this, despite the challenge of the environment.

[ Exyn ]

In this video object instance segmentation and shape completion are combined with classical regrasp planning to perform pick-place of novel objects. It is demonstrated with a UR5, Robotiq 85 parallel-jaw gripper, and Structure depth sensor with three rearrangement tasks: bin packing (minimize the height of the packing), placing bottles onto coasters, and arrange blocks from tallest to shortest (according to the longest edge). The system also accounts for uncertainty in the segmentation/completion by avoiding grasping or placing on parts of the object where perceptual uncertainty is predicted to be high.

[ Paper ] via [ Northeastern ]

Thanks Marcus!

U can’t touch this!

[ University of Tokyo ]

We introduce a way to enable more natural interaction between humans and robots through Mixed Reality, by using a shared coordinate system. Azure Spatial Anchors, which already supports colocalizing multiple HoloLens and smartphone devices in the same space, has now been extended to support robots equipped with cameras. This allows humans and robots sharing the same space to interact naturally: humans can see the plan and intention of the robot, while the robot can interpret commands given from the person’s perspective. We hope that this can be a building block in the future of humans and robots being collaborators and coworkers.

[ Microsoft ]

Some very high jumps from the skinniest quadruped ever.

[ ODRI ]

In this video we present recent efforts to make our humanoid robot LOLA ready for multi-contact locomotion, i.e. additional hand-environment support for extra stabilization during walking.

[ TUM ]

Classic bike moves from Dr. Guero.

[ Dr. Guero ]

For a robotics company, iRobot is OLD.

[ iRobot ]

The Canadian Space Agency presents Juno, a preliminary version of a rover that could one day be sent to the Moon or Mars. Juno can navigate autonomously or be operated remotely. The Lunar Exploration Analogue Deployment (LEAD) consisted in replicating scenarios of a lunar sample return mission.

[ CSA ]

How exactly does the Waymo Driver handle a cat cutting across its driving path? Jonathan N., a Product Manager on our Perception team, breaks it all down for us.

Now do kangaroos.

[ Waymo ]

Jibo is hard at work at MIT playing games with kids.

Children’s creativity plummets as they enter elementary school. Social interactions with peers and playful environments have been shown to foster creativity in children. Digital pedagogical tools often lack the creativity benefits of co-located social interaction with peers. In this work, we leverage a social embodied robot as a playful peer and designed Escape!Bot, a game involving child-robot co-play, where the robot is a social agent that scaffolds for creativity during gameplay.

[ Paper ]

It’s nice when convenience stores are convenient even for the folks who have to do the restocking.

Who’s moving the crates around, though?

[ Telexistence ]

Hi, fans ! Join the ROS World 2020, opening November 12th , and see the footage of ROBOTIS’ ROS platform robots 🙂

[ ROS World 2020 ]

ML/RL methods are often viewed as a magical black box, and while that’s not true, learned policies are nonetheless a valuable tool that can work in conjunction with the underlying physics of the robot. In this video, Agility CTO Jonathan Hurst – wearing his professor hat at Oregon State University – presents some recent student work on using learned policies as a control method for highly dynamic legged robots.

[ Agility Robotics ]

Here’s an ICRA Legged Robots workshop talk from Marco Hutter at ETH Zürich, on Autonomy for ANYmal.

Recent advances in legged robots and their locomotion skills has led to systems that are skilled and mature enough for real-world deployment. In particular, quadrupedal robots have reached a level of mobility to navigate complex environments, which enables them to take over inspection or surveillance jobs in place like offshore industrial plants, in underground areas, or on construction sites. In this talk, I will present our research work with the quadruped ANYmal and explain some of the underlying technologies for locomotion control, environment perception, and mission autonomy. I will show how these robots can learn and plan complex maneuvers, how they can navigate through unknown environments, and how they are able to conduct surveillance, inspection, or exploration scenarios.

[ RSL ] Continue reading

Posted in Human Robots

#437562 Video Friday: Aquanaut Robot Takes to ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here's what we have so far (send us your events!):

IROS 2020 – October 25-25, 2020 – [Online]
ICSR 2020 – November 14-16, 2020 – Golden, Colo., USA
Bay Area Robotics Symposium – November 20, 2020 – [Online]
ACRA 2020 – December 8-10, 2020 – [Online]
Let us know if you have suggestions for next week, and enjoy today's videos.

To prepare the Perseverance rover for its date with Mars, NASA’s Mars 2020 mission team conducted a wide array of tests to help ensure a successful entry, descent and landing at the Red Planet. From parachute verification in the world’s largest wind tunnel, to hazard avoidance practice in Death Valley, California, to wheel drop testing at NASA’s Jet Propulsion Laboratory and much more, every system was put through its paces to get ready for the big day. The Perseverance rover is scheduled to land on Mars on February 18, 2021.

[ JPL ]

Awesome to see Aquanaut—the “underwater transformer” we wrote about last year—take to the ocean!

Also their new website has SHARKS on it.

[ HMI ]

Nature has inspired engineers at UNSW Sydney to develop a soft fabric robotic gripper which behaves like an elephant's trunk to grasp, pick up and release objects without breaking them.

[ UNSW ]

Collaborative robots offer increased interaction capabilities at relatively low cost but, in contrast to their industrial counterparts, they inevitably lack precision. We address this problem by relying on a dual-arm system with laser-based sensing to measure relative poses between objects of interest and compensate for pose errors coming from robot proprioception.

[ Paper ]

Developed by NAVER LABS, with Korea University of Technology & Education (Koreatech), the robot arm now features an added waist, extending the available workspace, as well as a sensor head that can perceive objects. It has also been equipped with a robot hand “BLT Gripper” that can change to various grasping methods.

[ NAVER Labs ]

In case you were still wondering why SoftBank acquired Aldebaran and Boston Dynamics:

[ RobotStart ]

DJI's new Mini 2 drone is here with a commercial so hip it makes my teeth scream.

[ DJI ]

Using simple materials, such as plastic struts and cardboard rolls, the first prototype of the RBO Hand 3 is already capable of grasping a large range of different objects thanks to its opposable thumb.

The RBO Hand 3 performs an edge grasp before handing-over the object to a person. The hand actively exploits constraints in the environment (the tabletop) for grasping the object. Thanks to its compliance, this interaction is safe and robust.

[ TU Berlin ]

Flyability's Elios 2 helped researchers inspect Reactor Five at the Chernobyl nuclear disaster site in order to determine whether any uranium was present. Prior to this mission, Reactor Five had not been investigated since the disaster in April of 1986.

[ Flyability ]

Thanks Zacc!

SOTO 2 is here! Together with our development partners from the industry, we have greatly enhanced the SOTO prototype over the last two years. With the new version of the robot, Industry 4.0 will become a great deal more real: SOTO brings materials to the assembly line, just-in-time and completely autonomously.

[ Magazino ]

A drone that can fly sustainably for long distances over land and water, and can land almost anywhere, will be able to serve a wide range of applications. There are already drones that fly using ‘green’ hydrogen, but they either fly very slowly or cannot land vertically. That’s why researchers at TU Delft, together with the Royal Netherlands Navy and the Netherlands Coastguard, developed a hydrogen-powered drone that is capable of vertical take-off and landing whilst also being able to fly horizontally efficiently for several hours, much like regular aircraft. The drone uses a combination of hydrogen and batteries as its power source.

[ MAVLab ]

The National Nuclear User Facility for Hot Robotics (NNUF-HR) is an EPSRC funded facility to support UK academia and industry to deliver ground-breaking, impactful research in robotics and artificial intelligence for application in extreme and challenging nuclear environments.

[ NNUF ]

At the Karolinska University Laboratory in Sweden, an innovation project based around an ABB collaborative robot has increased efficiency and created a better working environment for lab staff.

[ ABB ]

What I find interesting about DJI's enormous new agricultural drone is that it's got a spinning obstacle detecting sensor that's a radar, not a lidar.

Also worth noting is that it seems to detect the telephone pole, but not the support wire that you can see in the video feed, although the visualization does make it seem like it can spot the power lines above.

[ DJI ]

Josh Pieper has spend the last year building his own quadruped, and you can see what he's been up to in just 12 minutes.

[ mjbots ]

Thanks Josh!

Dr. Ryan Eustice, TRI Senior Vice President of Automated Driving, delivers a keynote speech — “The Road to Vehicle Automation, a Toyota Guardian Approach” — to SPIE's Future Sensing Technologies 2020. During the presentation, Eustice provides his perspective on the current state of automated driving, summarizes TRI's Guardian approach — which amplifies human drivers, rather than replacing them — and summarizes TRI's recent developments in core AD capabilities.

[ TRI ]

Two excellent talks this week from UPenn GRASP Lab, from Ruzena Bajcsy and Vijay Kumar.

A panel discussion on the future of robotics and societal challenges with Dr. Ruzena Bajcsy as a Roboticist and Founder of the GRASP Lab.

In this talk I will describe the role of the White House Office of Science and Technology Policy in supporting science and technology research and education, and the lessons I learned while serving in the office. I will also identify a few opportunities at the intersection of technology and policy and broad societal challenges.

[ UPenn ]

The IROS 2020 “Perception, Learning, and Control for Autonomous Agile Vehicles” workshop is all online—here's the intro, but you can click through for a playlist that includes videos of the entire program, and slides are available as well.

[ NYU ] Continue reading

Posted in Human Robots

#437429 Insects found to use natural wing ...

A team of researchers from the University of California, the University of North Carolina at Chapel Hill and Pacific Northwest National Laboratory has found that insects use natural oscillations to stabilize their flight. In their study, published in the journal Science Robotics, the researchers used what they describe as “a type of calculus” (chronological calculus) to better understand the factors that are involved in keeping flapping winged insects aloft. Matěj Karásek, with Delft University of Technology has published a Focus piece in the same journal issue describing the work done by the team on this new effort. Continue reading

Posted in Human Robots

#437209 A Renaissance of Genomics and Drugs Is ...

The causes of aging are extremely complex and unclear. But with longevity clinical trials increasing, more answers—and questions—are emerging than ever before.

With the dramatic demonetization of genome reading and editing over the past decade, and Big Pharma, startups, and the FDA starting to face aging as a disease, we are starting to turn those answers into practical ways to extend our healthspan.

In this article, I’ll explore how genome sequencing and editing, along with new classes of anti-aging drugs, are augmenting our biology to further extend our healthy lives.

Genome Sequencing and Editing
Your genome is the software that runs your body. A sequence of 3.2 billion letters makes you “you.” These base pairs of A’s, T’s, C’s, and G’s determine your hair color, your height, your personality, your propensity for disease, your lifespan, and so on.

Until recently, it’s been very difficult to rapidly and cheaply “read” these letters—and even more difficult to understand what they mean. Since 2001, the cost to sequence a whole human genome has plummeted exponentially, outpacing Moore’s Law threefold. From an initial cost of $3.7 billion, it dropped to $10 million in 2006, and to $1,500 in 2015.

Today, the cost of genome sequencing has dropped below $600, and according to Illumina, the world’s leading sequencing company, the process will soon cost about $100 and take about an hour to complete.

This represents one of the most powerful and transformative technology revolutions in healthcare. When we understand your genome, we’ll be able to understand how to optimize “you.”

We’ll know the perfect foods, the perfect drugs, the perfect exercise regimen, and the perfect supplements, just for you.
We’ll understand what microbiome types, or gut flora, are ideal for you (more on this in a later article).
We’ll accurately predict how specific sedatives and medicines will impact you.
We’ll learn which diseases and illnesses you’re most likely to develop and, more importantly, how to best prevent them from developing in the first place (rather than trying to cure them after the fact).

CRISPR Gene Editing
In addition to reading the human genome, scientists can now edit a genome using a naturally occurring biological system discovered in 1987 called CRISPR/Cas9.

Short for Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9, the editing system was adapted from a naturally-occurring defense system found in bacteria.

Here’s how it works. The bacteria capture snippets of DNA from invading viruses (or bacteriophage) and use them to create DNA segments known as CRISPR arrays. The CRISPR arrays allow the bacteria to “remember” the viruses (or closely related ones), and defend against future invasions. If the viruses attack again, the bacteria produce RNA segments from the CRISPR arrays to target the viruses’ DNA. The bacteria then use Cas9 to cut the DNA apart, which disables the virus.

Most importantly, CRISPR is cheap, quick, easy to use, and more accurate than all previous gene editing methods. As a result, CRISPR/Cas9 has swept through labs around the world as the way to edit a genome. A short search in the literature will show an exponential rise in the number of CRISPR-related publications and patents.

2018: Filled With CRISPR Breakthroughs
Early results are impressive. Researchers have used CRISPR to genetically engineer cocaine resistance into mice, reverse the gene defect causing Duchenne muscular dystrophy (DMD) in dogs, and reduce genetic deafness in mice.

Already this year, CRISPR-edited immune cells have been shown to successfully kill cancer cells in human patients. Researchers have discovered ways to activate CRISPR with light and use the gene-editing technology to better understand Alzheimer’s disease progression.

With great power comes great responsibility, and the opportunity for moral and ethical dilemmas. In 2015, Chinese scientists sparked global controversy when they first edited human embryo cells in the lab with the goal of modifying genes that would make the child resistant to smallpox, HIV, and cholera. Three years later, in November 2018, researcher He Jiankui informed the world that the first set of CRISPR-engineered female twins had been delivered.

To accomplish his goal, Jiankui deleted a region of a receptor on the surface of white blood cells known as CCR5, introducing a rare, natural genetic variation that makes it more difficult for HIV to infect its favorite target, white blood cells. Because Jiankui forged ethical review documents and misled doctors in the process, he was sentenced to three years in prison and fined $429,000 last December.

Coupled with significant ethical conversations necessary for progress, CRISPR will soon provide us the tools to eliminate diseases, create hardier offspring, produce new environmentally resistant crops, and even wipe out pathogens.

Senolytics, Nutraceuticals, and Pharmaceuticals
Over the arc of your life, the cells in your body divide until they reach what is known as the Hayflick limit, or the number of times a normal human cell population will divide before cell division stops, which is typically about 50 divisions.

What normally follows next is programmed cell death or destruction by the immune system. A very small fraction of cells, however, become senescent cells and evade this fate to linger indefinitely. These lingering cells secrete a potent mix of molecules that triggers chronic inflammation, damages the surrounding tissue structures, and changes the behavior of nearby cells for the worse. Senescent cells appear to be one of the root causes of aging, causing everything from fibrosis and blood vessel calcification to localized inflammatory conditions such as osteoarthritis to diminished lung function.

Fortunately, both the scientific and entrepreneurial communities have begun to work on senolytic therapies, moving the technology for selectively destroying senescent cells out of the laboratory and into a half-dozen startup companies.

Prominent companies in the field include the following:

Unity Biotechnology is developing senolytic medicines to selectively eliminate senescent cells with an initial focus on delivering localized therapy in osteoarthritis, ophthalmology, and pulmonary disease.

Oisin Biotechnologies is pioneering a programmable gene therapy that can destroy cells based on their internal biochemistry.

SIWA Therapeutics is working on an immunotherapy approach to the problem of senescent cells.

In recent years, researchers have identified or designed a handful of senolytic compounds that can curb aging by regulating senescent cells. Two of these drugs that have gained mainstay research traction are rapamycin and metformin.

(1) Rapamycin

Originally extracted from bacteria found on Easter Island, rapamycin acts on the m-TOR (mechanistic target of rapamycin) pathway to selectively block a key protein that facilitates cell division. Currently, rapamycin derivatives are widely used for immunosuppression in organ and bone marrow transplants. Research now suggests that use results in prolonged lifespan and enhanced cognitive and immune function.

PureTech Health subsidiary resTORbio (which went public in 2018) is working on a rapamycin-based drug intended to enhance immunity and reduce infection. Their clinical-stage RTB101 drug works by inhibiting part of the mTOR pathway.

Results of the drug’s recent clinical trial include decreased incidence of infection, improved influenza vaccination response, and a 30.6 percent decrease in respiratory tract infection.

Impressive, to say the least.

(2) Metformin

Metformin is a widely-used generic drug for mitigating liver sugar production in Type 2 diabetes patients. Researchers have found that metformin also reduces oxidative stress and inflammation, which otherwise increase as we age. There is strong evidence that metformin can augment cellular regeneration and dramatically mitigate cellular senescence by reducing both oxidative stress and inflammation.

Over 100 studies registered on ClinicalTrials.gov are currently following up on strong evidence of metformin’s protective effect against cancer.

(3) Nutraceuticals and NAD+

Beyond cellular senescence, certain critical nutrients and proteins tend to decline as a function of age. Nutraceuticals combat aging by supplementing and replenishing these declining nutrient levels.

NAD+ exists in every cell, participating in every process from DNA repair to creating the energy vital for cellular processes. It’s been shown that NAD+ levels decline as we age.

The Elysium Health Basis supplement aims to elevate NAD+ levels in the body to extend one’s lifespan. Elysium’s first clinical study reports that Basis increases NAD+ levels consistently by a sustained 40 percent.

Conclusion
These are just a taste of the tremendous momentum that longevity and aging technology has right now. As artificial intelligence and quantum computing transform how we decode our DNA and how we discover drugs, genetics and pharmaceuticals will become truly personalized.

The next article in this series will demonstrate how artificial intelligence is converging with genetics and pharmaceuticals to transform how we approach longevity, aging, and vitality.

We are edging closer toward a dramatically extended healthspan—where 100 is the new 60. What will you create, where will you explore, and how will you spend your time if you are able to add an additional 40 healthy years to your life?

Join Me
(1) A360 Executive Mastermind: If you’re an exponentially and abundance-minded entrepreneur who would like coaching directly from me, consider joining my Abundance 360 Mastermind, a highly selective community of 360 CEOs and entrepreneurs who I coach for 3 days every January in Beverly Hills, Ca. Through A360, I provide my members with context and clarity about how converging exponential technologies will transform every industry. I’m committed to running A360 for the course of an ongoing 25-year journey as a “countdown to the Singularity.”

If you’d like to learn more and consider joining our 2021 membership, apply here.

(2) Abundance-Digital Online Community: I’ve also created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is Singularity University’s ‘onramp’ for exponential entrepreneurs—those who want to get involved and play at a higher level. Click here to learn more.

(Both A360 and Abundance-Digital are part of Singularity University—your participation opens you to a global community.)

This article originally appeared on diamandis.com. Read the original article here.

Image Credit: Arek Socha from Pixabay Continue reading

Posted in Human Robots

#437171 Scientists Tap the World’s Most ...

In The Hitchhiker’s Guide to the Galaxy by Douglas Adams, the haughty supercomputer Deep Thought is asked whether it can find the answer to the ultimate question concerning life, the universe, and everything. It replies that, yes, it can do it, but it’s tricky and it’ll have to think about it. When asked how long it will take it replies, “Seven-and-a-half million years. I told you I’d have to think about it.”

Real-life supercomputers are being asked somewhat less expansive questions but tricky ones nonetheless: how to tackle the Covid-19 pandemic. They’re being used in many facets of responding to the disease, including to predict the spread of the virus, to optimize contact tracing, to allocate resources and provide decisions for physicians, to design vaccines and rapid testing tools, and to understand sneezes. And the answers are needed in a rather shorter time frame than Deep Thought was proposing.

The largest number of Covid-19 supercomputing projects involves designing drugs. It’s likely to take several effective drugs to treat the disease. Supercomputers allow researchers to take a rational approach and aim to selectively muzzle proteins that SARS-CoV-2, the virus that causes Covid-19, needs for its life cycle.

The viral genome encodes proteins needed by the virus to infect humans and to replicate. Among these are the infamous spike protein that sniffs out and penetrates its human cellular target, but there are also enzymes and molecular machines that the virus forces its human subjects to produce for it. Finding drugs that can bind to these proteins and stop them from working is a logical way to go.

The Summit supercomputer at Oak Ridge National Laboratory has a peak performance of 200,000 trillion calculations per second—equivalent to about a million laptops. Image credit: Oak Ridge National Laboratory, U.S. Dept. of Energy, CC BY

I am a molecular biophysicist. My lab, at the Center for Molecular Biophysics at the University of Tennessee and Oak Ridge National Laboratory, uses a supercomputer to discover drugs. We build three-dimensional virtual models of biological molecules like the proteins used by cells and viruses, and simulate how various chemical compounds interact with those proteins. We test thousands of compounds to find the ones that “dock” with a target protein. Those compounds that fit, lock-and-key style, with the protein are potential therapies.

The top-ranked candidates are then tested experimentally to see if they indeed do bind to their targets and, in the case of Covid-19, stop the virus from infecting human cells. The compounds are first tested in cells, then animals, and finally humans. Computational drug discovery with high-performance computing has been important in finding antiviral drugs in the past, such as the anti-HIV drugs that revolutionized AIDS treatment in the 1990s.

World’s Most Powerful Computer
Since the 1990s the power of supercomputers has increased by a factor of a million or so. Summit at Oak Ridge National Laboratory is presently the world’s most powerful supercomputer, and has the combined power of roughly a million laptops. A laptop today has roughly the same power as a supercomputer had 20-30 years ago.

However, in order to gin up speed, supercomputer architectures have become more complicated. They used to consist of single, very powerful chips on which programs would simply run faster. Now they consist of thousands of processors performing massively parallel processing in which many calculations, such as testing the potential of drugs to dock with a pathogen or cell’s proteins, are performed at the same time. Persuading those processors to work together harmoniously is a pain in the neck but means we can quickly try out a lot of chemicals virtually.

Further, researchers use supercomputers to figure out by simulation the different shapes formed by the target binding sites and then virtually dock compounds to each shape. In my lab, that procedure has produced experimentally validated hits—chemicals that work—for each of 16 protein targets that physician-scientists and biochemists have discovered over the past few years. These targets were selected because finding compounds that dock with them could result in drugs for treating different diseases, including chronic kidney disease, prostate cancer, osteoporosis, diabetes, thrombosis and bacterial infections.

Scientists are using supercomputers to find ways to disable the various proteins—including the infamous spike protein (green protrusions)—produced by SARS-CoV-2, the virus responsible for Covid-19. Image credit: Thomas Splettstoesser scistyle.com, CC BY-ND

Billions of Possibilities
So which chemicals are being tested for Covid-19? A first approach is trying out drugs that already exist for other indications and that we have a pretty good idea are reasonably safe. That’s called “repurposing,” and if it works, regulatory approval will be quick.

But repurposing isn’t necessarily being done in the most rational way. One idea researchers are considering is that drugs that work against protein targets of some other virus, such as the flu, hepatitis or Ebola, will automatically work against Covid-19, even when the SARS-CoV-2 protein targets don’t have the same shape.

Our own work has now expanded to about 10 targets on SARS-CoV-2, and we’re also looking at human protein targets for disrupting the virus’s attack on human cells. Top-ranked compounds from our calculations are being tested experimentally for activity against the live virus. Several of these have already been found to be active.The best approach is to check if repurposed compounds will actually bind to their intended target. To that end, my lab published a preliminary report of a supercomputer-driven docking study of a repurposing compound database in mid-February. The study ranked 8,000 compounds in order of how well they bind to the viral spike protein. This paper triggered the establishment of a high-performance computing consortium against our viral enemy, announced by President Trump in March. Several of our top-ranked compounds are now in clinical trials.

Also, we and others are venturing out into the wild world of new drug discovery for Covid-19—looking for compounds that have never been tried as drugs before. Databases of billions of these compounds exist, all of which could probably be synthesized in principle but most of which have never been made. Billion-compound docking is a tailor-made task for massively parallel supercomputing.

Dawn of the Exascale Era
Work will be helped by the arrival of the next big machine at Oak Ridge, called Frontier, planned for next year. Frontier should be about 10 times more powerful than Summit. Frontier will herald the “exascale” supercomputing era, meaning machines capable of 1,000,000,000,000,000,000 calculations per second.

Although some fear supercomputers will take over the world, for the time being, at least, they are humanity’s servants, which means that they do what we tell them to. Different scientists have different ideas about how to calculate which drugs work best—some prefer artificial intelligence, for example—so there’s quite a lot of arguing going on.

Hopefully, scientists armed with the most powerful computers in the world will, sooner rather than later, find the drugs needed to tackle Covid-19. If they do, then their answers will be of more immediate benefit, if less philosophically tantalizing, than the answer to the ultimate question provided by Deep Thought, which was, maddeningly, simply 42.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Image credit: NIH/NIAID Continue reading

Posted in Human Robots